31 January 2019 
EMA/56302/2019 
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (post authorisation) 
Forxiga  
dapagliflozin  
On 31 January 2019, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive 
opinion recommending a change to the terms of the marketing authorisation for the medicinal product 
Forxiga. The marketing authorisation holder for this medicinal product is AstraZeneca AB. 
The CHMP adopted a new indication as follows:2 
“Forxiga is indicated in adults for the treatment of insufficiently controlled 
• 
• 
type 2 diabetes mellitus as an adjunct to diet and exercise, to improve glycaemic control, 
−  as monotherapy when metformin is considered inappropriate due to intolerance. 
− 
in addition to other medicinal products for the treatment of type 2 diabetes. 
type 1 diabetes mellitus as an adjunct to insulin in patients with BMI ≥ 27 kg/m2, when 
insulin alone does not provide adequate glycaemic control despite optimal insulin therapy. 
For clinical study results with respect to populations studied, effects on glycaemic control and combinations 
with other medicinal products see sections 4.4, 4.5 and 5.1.” 
Detailed recommendations for the use of this product will be described in the updated summary of product 
characteristics (SmPC), which will be published in the revised European Public Assessment Report (EPAR), 
and will be available in all official European Union languages after a decision on this change to the marketing 
authorisation has been granted by the European Commission. 
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 days 
from adoption of the opinion 
2 New text in bold 
30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom 
Telephone  +44 (0)20 3660 6000  Facsimile +44 (0)20 3660 5520 
Send a question via our website www.ema.europa.eu/contact 
An agency of the European Union   
© European Medicines Agency, 2019. Reproduction is authorised provided the source is acknowledged. 
 
  
 
 
 
  
 
 
                                                
